Fig. 3: Loss of SDHC improves tumour cell growth in hypoxia. | Communications Biology

Fig. 3: Loss of SDHC improves tumour cell growth in hypoxia.

From: Genome-wide CRISPR/Cas9 deletion screen defines mitochondrial gene essentiality and identifies routes for tumour cell viability in hypoxia

Fig. 3

a Chart shows all genes with significantly enriched sgRNAs (robust rank aggregation (RRA) score, positive) in hypoxia-glucose at different FDR thresholds. b Chart shows relative growth of U2OS cells cultured for 5 days in normoxia or hypoxia (1% O2) treated with non-targeting control siRNA (siCtrl) or siRNA targeting SDHC (siSDHC). n = 3. Mean ± S.D.; n.s. not significant; ***p < 0.001. c Western blots show expression of SDHC, and BNIP3 in U2OS cells incubated for 5d in normoxia (Nor) or hypoxia (Hyp, 1% O2). β-Actin used as a loading control. d Chart shows the relative density of SDHC bands from samples in (c). n = 3; mean ± S.D.; **p < 0.01. e Charts show expression of SDHC and EGLN3 from U2OS cells incubated for 5d in normoxia or hypoxia (1% O2). n = 3; mean ± S.D.; **p < 0.01. f Charts show relative growth of U2OS cells incubated for 5d in normoxia or hypoxia (1% O2), in the presence of 25 mM galactose, treated with non-targeting control siRNA (siCtrl) or siRNA targeting SDHC (siSDHC). n = 3; mean ± S.D.; n.s. not significant; *p < 0.05; **p < 0.01.

Back to article page